ARTICLE | Company News
AAIPharma, Cortria deal
December 22, 2008 8:00 AM UTC
Cortria received an exclusive license to use AAIPharma's ProCR controlled-release drug delivery technology with TRIA-662 in North America. The metabolite of niacin is in Phase II testing to treat dysl...